BioCryst Pharma (NASDAQ: BCRX) reported Q2 EPS of ($0.21), $0.02 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $3.1 million versus the consensus estimate of $5.79 million.

Cash, cash equivalents and investments totaled $95.6 million at June 30, 2017, and reflect an increase from $65.1 million at December 31, 2016. Net operating cash use for the second quarter of 2017 was $12.2 million, and the first six months of 2017 was $21.0 million, which excludes the impact of $47.8 million of net proceeds from our March 2017 public offering.

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.